PHYSICAL ACTIVITY IN DAILY LIFE, EXERCISE CAPACITY AND QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE ON INFLIXIMAB-INDUCED REMISSION: A PRELIMINARY STUDY

Arq Gastroenterol. 2019 Oct-Dec;56(4):351-356. doi: 10.1590/S0004-2803.201900000-65.

Abstract

Background: Physical activity in daily life and exercise capacity have not been assessed in patients with Crohn's disease to date.

Objective: To evaluate the physical activity in daily life, exercise capacity, quality of life, and prevalence of mood disorders in patients with moderate-to-severe Crohn's disease on infliximab-induced remission and the possible associations among variables.

Methods: A cross-sectional preliminary study was conducted. Twenty-six patients with Crohn's disease and 20 controls were selected. Participants underwent evaluation of physical activity in daily life (triaxial accelerometer), exercise capacity (shuttle walk test), handgrip strength, quality of life, and presence of mood disorders.

Results: The number of steps taken (7446±3081 vs 7898±2487), active time (80.6±42 vs 89.7±24.3min), shuttle walk test distance [665 (405) vs 710 (409) m] and handgrip strength [31 (15) vs 29 (20) kgf did not show any difference between the patients with Crohn's disease and the controls. The time spent lying down [95.8 (68.8) vs 60.9 (74.7) min] was greater and some domains of the quality of life were superior in the patients with Crohn's disease. No correlation was observed between the physical activity in daily life and quality of life or presence of mood disorders in patients with Crohn's disease.

Conclusion: Patients with Crohn's disease on infliximab-induced remission, despite to more time spent lying down, they have the same level of physical activity in daily life and exercise capacity min compared with the controls.

MeSH terms

  • Adult
  • Case-Control Studies
  • Crohn Disease / drug therapy*
  • Crohn Disease / psychology*
  • Crohn Disease / radiotherapy
  • Cross-Sectional Studies
  • Exercise / psychology*
  • Exercise Tolerance
  • Female
  • Gastrointestinal Agents / administration & dosage*
  • Humans
  • Infliximab / administration & dosage*
  • Male
  • Mood Disorders / psychology*
  • Prevalence
  • Quality of Life / psychology*
  • Severity of Illness Index

Substances

  • Gastrointestinal Agents
  • Infliximab